Page 10 - Tata_Chemicals_yearly-reports-2018-19
P. 10

Performance Highlights for FY 2018-19







                         Financial capital   #
                         Financial capital represents the pool of funds, including both debt and equity finance, that is available to our
                         organisation. We rely on multiple sources of funds and put them to use for the acquisition of manufactured
                         capital to strengthen the balance sheet.






                                                                                      Market
           EBITDA                   PBT                      PAT                      capitalisation*
           D2,095 Cr.               D1,742 Cr.               D1,395 Cr.               D15,000 Cr.


           D2,191 Cr.               D1,620 Cr.               D1,560 Cr.               D17,251 Cr.
           FY 2017-18               FY 2017-18               FY 2017-18               FY 2017-18
           # For continuing operations only                                           *As on March 31, 2019


                         Manufactured capital
                         Manufacturing capital represents our plants, warehouses, logistics facilities and all the physical assets that we
                         use for producing basic and agro chemicals, consumer food, nutritional products and seeds. We continue to
                         invest in the manufactured capital to build capacities and enhance operational efficiency.



           Soda Ash                 Sodium Bicarbonate       Branded salt             Cement
           production               production               production*              production
           3,634 KT                 220 KT                   1,131 KT                 409 KT



                                                              * includes I Shakti Salt


                         Intellectual capital

                         Intellectual capital represents our scientific knowledge, research & development capabilities and innovation
                         quotient which is core to our business. We have put a strong emphasis on R&D to come up with new and
                         better products that enhance our competitiveness.






           Investment in R&D                        Patents filed
           D38 Cr.                                  5





           08
   5   6   7   8   9   10   11   12   13   14   15